Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan And Medicis/Ipsen Battle Over Marketing Advantage Of REMS

Executive Summary

FDA's decision to require a Risk Evaluation and Mitigation Strategy for botulinum toxin products has opened up a marketing battle between Allergan's long-standing Botox and Ipsen/Medicis' the new-to-the-block Dysport

You may also be interested in...



Specialty Pharmacies Could Be Selling Point If FDA Approves Tasimelteon

A Nov. 14 advisory committee gave near-unanimous support for Vanda’s sleep disorder drug on questions about its indication, endpoints, efficacy and safety.

Botox Safety Emphasized By FDA As Botulinum Toxins Get New Generic Names

Safety efforts designed to discourage interchanging products will benefit the market leader.

Health Reform And Rare Diseases: Orphan Drugs May Do Well Amid Changes

Advocates for patients with rare diseases are urging Congress to build in special considerations for treatments for rare diseases in several key provisions of health care reform

Related Content

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel